Hormone Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Hormone Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) [Phase 3]
A Phase 3 study (SERENA-6) is evaluating AZD9833 plus a CDK4/6 inhibitor in HR+/HER2-negative breast cancer with ESR1 mutation; the trial is…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy [NA]
This document notes the termination of a feasibility trial evaluating a web-based app to improve adherence to endocrine therapy in hormone r…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer [Phase 2]
Phase 2 trial evaluating Fluzoparib plus chemotherapy as neoadjuvant therapy for HRD-positive, hormone receptor-positive/HER2-negative breas…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer [Phase 1]
A completed Phase 1 trial evaluated the combination of capecitabine and cemiplimab in patients with metastatic breast cancer, including horm…
-
CLINICAL_TRIALS trial_result · 2026-03-12Clinical Trial Update: Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients [Phase 2]
Phase 2 neoadjuvant trial comparing chemotherapy versus letrozole plus abemaciclib in HR+/HER2- high/intermediate risk early breast cancer; …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-06Clinical Trial Update: Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer
A clinical trial investigating adherence to aromatase inhibitors with or without abemaciclib in early-stage HER2-negative breast cancer is c…
-
CLINICAL_TRIALS trial_result · 2026-03-03Clinical Trial Update: Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) [Phase 2]
A Phase 2 ComboMATCH trial evaluating fulvestrant plus binimetinib for NF1-mutant, hormone receptor-positive metastatic breast cancer was te…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.
This completed clinical trial update describes real-world treatment patterns and clinical outcomes for patients with HR+/HER2- advanced/meta…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer [Phase 3]
Phase 3 trial evaluating metronomic capecitabine plus an aromatase inhibitor as first-line therapy for HR-positive, HER2-negative metastatic…
-
CLINICAL_TRIALS trial_result · 2026-02-13Clinical Trial Update: ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer [Phase 2]
A Phase 2 trial evaluating ARX788 for HER2-low breast cancer (locally advanced unresectable or metastatic) is currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: A Study of Revaree Plus in People With Breast Cancer [Phase 4]
Phase 4 clinical trial update for Revaree Plus in breast cancer patients is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer [Phase 3]
A Phase 3 trial update reports on neoadjuvant Pyrotinib for hormone-receptor-positive, HER2-low high-risk early breast cancer, with the tria…
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating sacituzumab govitecan in combination with atropine to improve tolerability in advanced breast cancers, i…
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy [Phase 2]
Phase 2 trial evaluating pembrolizumab in hormone receptor-positive, localized inflammatory breast cancer patients on hormone therapy who di…
-
CLINICAL_TRIALS trial_result · 2026-01-02Clinical Trial Update: Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer [Phase 2]
Phase 2 trial evaluating alpelisib in combination with continued endocrine therapy after progression in HR-positive, HER2-negative, PIK3CA-m…
-
CLINICAL_TRIALS trial_result · 2025-12-04Clinical Trial Update: Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED [Phase 2]
A Phase 2 trial (PRIMED) evaluating a preventive strategy for IMMU132-related adverse events in triple-negative and HR+/HER2-negative breast…
-
CLINICAL_TRIALS trial_result · 2025-10-31Clinical Trial Update: Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)
A clinical trial evaluating aromatase inhibitor-associated musculoskeletal symptoms in breast cancer survivors has completed.
-
CLINICAL_TRIALS trial_result · 2025-10-29Clinical Trial Update: A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer [Phase 3]
Phase 3 clinical trial evaluating elinzanetant versus placebo for vasomotor symptoms caused by adjuvant endocrine therapy in women with, or …
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC
This completed clinical trial update analyzes treatment patterns and clinical outcomes of palbociclib combinations in hormone receptor-posit…
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer [Phase 1, Phase 2]
This update covers a dose-escalation/expansion study of OP-1250 in advanced HR+, HER2- breast cancer, which completed Phase 1 and Phase 2. N…
-
CLINICAL_TRIALS trial_result · 2025-08-21Clinical Trial Update: Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer [Phase 2]
This is a Phase 2 clinical trial update evaluating adebrelimab in combination with dalpiciclib and standard endocrine therapy for HR+/HER2- …
-
CLINICAL_TRIALS trial_result · 2025-08-12Clinical Trial Update: Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01) [Phase 2]
Phase 2 neoadjuvant trial evaluating chemotherapy in combination with toripalimab for hormone receptor-positive, HER2-negative breast cancer…
-
CLINICAL_TRIALS trial_result · 2025-07-25Clinical Trial Update: Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
A retrospective analysis examines second-line therapies used after progression on a CDK4/6 inhibitor plus hormonal therapy in patients with …
-
CLINICAL_TRIALS trial_result · 2025-07-25Clinical Trial Update: A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer
This is a completed real-world study of ribociclib used as first-line therapy for metastatic hormone receptor-positive, HER2-negative breast…
-
CLINICAL_TRIALS trial_result · 2025-07-20Clinical Trial Update: Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer [Phase 2]
Phase 2 trial evaluating the impact of combining endocrine therapy with abemaciclib on host and tumor immune cell repertoire in advanced ER+…